

Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-217 (Canceled)

Claim 218 (Previously presented) An isolated nucleic acid encoding a human or rat neuropeptide FF2 (NPFF2) receptor, wherein the human NPFF2 receptor has an amino acid sequence identical to the amino acid sequence shown in Figure 8 (SEQ ID NO: 6) or that encoded by plasmid pcDNA3.1-hNPFF2b (ATCC Accession No. 203255); and the rat NPFF2 receptor has an amino acid sequence identical to the amino acid sequence shown in Figures 23A-23B (SEQ ID NO: 44) or that encoded by plasmid pcDNA3.1-rNPFF2-f (Patent Deposit Designation No. PTA-535).

Claim 219 (Previously presented) The nucleic acid of claim 218, wherein the nucleic acid is DNA.

Claim 220 (Previously presented) The DNA of claim 219, wherein the DNA is cDNA.

Claim 221 (Previously presented) The nucleic acid of claim 218, wherein the nucleic acid is RNA.

Claim 222 (Previously presented) A vector comprising the nucleic acid of claim 218.

Claim 223 (Previously presented) A vector of claim 222, adapted for expression in a cell which comprises the regulatory elements necessary for expression of the nucleic acid in the cell operatively linked to the

nucleic acid encoding the receptor so as to permit expression thereof, wherein the cell is a bacterial, amphibian, yeast, insect or mammalian cell.

Claim 224 (Previously presented) The vector of claim 223, wherein the vector is a baculovirus.

Claim 225 (Previously presented) The vector of claim 222, wherein the vector is a plasmid.

Claim 226 (Previously presented) The plasmid of claim 225 designated pcDNA3.1-hNPFF2b (ATCC Accession No. 203255).

Claim 227 (Previously presented) The plasmid of claim 225 designated pcDNA3.1-rNPFF2-f (Patent Deposit Designation No. PTA-535).

Claim 228 (Previously presented) An isolated cell comprising the vector of claim 223.

Claim 229 (Previously presented) The isolated cell of claim 228, wherein the cell is a non-mammalian cell.

Claim 230 (Previously presented) The isolated cell of claim 229, wherein the non-mammalian cell is a *Xenopus* oocyte cell or a *Xenopus* melanophore cell.

Claim 231 (Previously presented) The isolated cell of claim 228, wherein the cell is a mammalian cell.

Claim 232 (Previously presented) The isolated mammalian cell of claim 231, wherein the cell is a COS-7 cell, a 293 human embryonic kidney cell, a NIH-3T3 cell, a LM(tk-) cell, a mouse Y1 cell, or a CHO cell.

Claim 233 (Previously presented) An insect cell comprising the vector of claim 223.

Applicants: Christophe P.G. Gerald, et al.
Application No: 09/538,036
Filed: March 29, 2000
Page 4

Claim 234 (Previously presented) An insect cell of claim 233, wherein the insect cell is an Sf9 cell, an Sf21 cell or a Trichoplusia ni 5B1-4 cell.

Claim 235 (Currently amended) A membrane preparation isolated from the cell of any one of claims 228, 229, 231, 232, 233 or 234, wherein the membrane preparation comprises said human neuropeptide FF2 (NPFF2) receptor or said rat neuropeptide FF2 (NPFF2) receptor.